Robert Molokie

Dr. Robert Molokie


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Nursing Clinics of North America
Verified
Journal Article
Closed access
DWDiana J Wilkie
Diana J Wilkie
BJBonnye Johnson
Bonnye Johnson
AMA. Kyle Mack
A. Kyle Mack
RLRichard Labotka
Richard Labotka
RMRobert Molokie
Robert Molokie

1 June 2015 in Pain Management Nursing
Verified
Journal Article
Closed access
MEMiriam O. Ezenwa
Miriam O. Ezenwa
RMRobert Molokie
Robert Molokie
DWDiana J Wilkie
Diana J Wilkie
MSMarie L. Suarez
Marie L. Suarez
YYYingwei Yao
Yingwei Yao

1 January 2014 in European Journal of Pharmacology
Verified
Journal Article
Closed access
RMRobert Molokie
Robert Molokie
DWDiana J. Wilkie
Diana J. Wilkie
HWHarriett Wittert
Harriett Wittert
MSMarie L. Suarez
Marie L. Suarez
YYYingwei Yao
Yingwei Yao
ZWZaijie J. Wang
Zaijie J. Wang

17 August 2018 in Experimental Hematology
Verified
Journal Article
Closed access
ARAngela Rivers
Angela Rivers
KVKestis Vaitkus
Kestis Vaitkus
RJRamasamy Jagadeeswaran
Ramasamy Jagadeeswaran
MRMaria Armila Ruiz
Maria Armila Ruiz
VIVinzon Ibanez
Vinzon Ibanez
DLDonald Lavelle
Donald Lavelle


26 February 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSantosh Saraf
Santosh Saraf
KGKrishna Ghimire
Krishna Ghimire
PPPritesh Patel
Pritesh Patel
KSKaren Sweiss
Karen Sweiss
MGMichel Gowhari
Michel Gowhari
DRDamiano Rondelli
Damiano Rondelli
Patients with sickle cell disease (SCD) have access to fewer health care resources and therapies compared to other diseases, which contributes to increased morbidity and health care utilization. We compared health care utilization (inpatient hospital days, emergency care visits) and health care-related costs between SCD adults that underwent hematopoietic stem cell transplantation (HSCT) using a nonmyeloblative conditioning regimen versus those referred for HSCT but did not proceed due to lack of an HLA-matched sibling donor, denial by insurance, red blood cell antibodies to the potential donor, or declining further evaluation. Between 8/2011 and 4/2016, 83 SCD patients were referred for allogeneic HSCT and 16 underwent the procedure. The HSCT and non-HSCT groups were similar by age, sex, prior SCD-related therapy and complications. Compared to pre HSCT, significantly fewer inpatient hospital days (median of 1 versus 22 days, P = 0.003) and emergency care visits (median of 1 versus 4 visits, P = 0.04) were observed by the 2nd year post-HSCT. Similar results were observed in comparison to the standard-of-care group (median of 1 versus 12 hospital days, P = 0.002; median of 1 versus 3 emergency visits, P = 0.03). Lower health care costs were observed by the 2nd year post-HSCT (median of $16,281 versus $64,634 pre-HSCT (P = 0.01) and versus $54,082 in the standard-of-care group (P = 0.05). A median reduction of -$20,833/patient/year (IQR, -$67,078-+$4,442/patient/year) in health care costs compared to pre-HSCT was observed in the 2nd year post-HSCT. In conclusion, allogeneic HSCT leads to improvements in health care utilization and costs compared to standard-of-care therapy in high-risk SCD adults.